NeuroPace (NPCE) Competitors $11.69 -0.29 (-2.42%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NPCE vs. KMTS, PLSE, CDRE, TNDM, BLFS, LQDA, FNA, AORT, MDXG, and INMDShould you be buying NeuroPace stock or one of its competitors? The main competitors of NeuroPace include Kestra Medical Technologies (KMTS), Pulse Biosciences (PLSE), Cadre (CDRE), Tandem Diabetes Care (TNDM), BioLife Solutions (BLFS), Liquidia (LQDA), Paragon 28 (FNA), Artivion (AORT), MiMedx Group (MDXG), and InMode (INMD). These companies are all part of the "medical equipment" industry. NeuroPace vs. Kestra Medical Technologies Pulse Biosciences Cadre Tandem Diabetes Care BioLife Solutions Liquidia Paragon 28 Artivion MiMedx Group InMode Kestra Medical Technologies (NASDAQ:KMTS) and NeuroPace (NASDAQ:NPCE) are both small-cap manufacturing companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment. Does the media favor KMTS or NPCE? In the previous week, Kestra Medical Technologies had 1 more articles in the media than NeuroPace. MarketBeat recorded 5 mentions for Kestra Medical Technologies and 4 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.59 beat Kestra Medical Technologies' score of 0.64 indicating that NeuroPace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kestra Medical Technologies 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeuroPace 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts rate KMTS or NPCE? Kestra Medical Technologies presently has a consensus target price of $27.50, indicating a potential upside of 14.30%. NeuroPace has a consensus target price of $15.20, indicating a potential upside of 30.03%. Given NeuroPace's higher possible upside, analysts plainly believe NeuroPace is more favorable than Kestra Medical Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kestra Medical Technologies 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83NeuroPace 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is KMTS or NPCE more profitable? Kestra Medical Technologies has a net margin of 0.00% compared to NeuroPace's net margin of -36.74%. Kestra Medical Technologies' return on equity of 0.00% beat NeuroPace's return on equity.Company Net Margins Return on Equity Return on Assets Kestra Medical TechnologiesN/A N/A N/A NeuroPace -36.74%-205.41%-28.29% Do insiders & institutionals have more ownership in KMTS or NPCE? 78.8% of NeuroPace shares are owned by institutional investors. 22.2% of NeuroPace shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has better earnings & valuation, KMTS or NPCE? Kestra Medical Technologies has higher earnings, but lower revenue than NeuroPace. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKestra Medical Technologies$52.64M23.47N/AN/AN/ANeuroPace$79.91M4.79-$32.96M-$0.95-12.31 Does the MarketBeat Community believe in KMTS or NPCE? NeuroPace received 26 more outperform votes than Kestra Medical Technologies when rated by MarketBeat users. However, 71.43% of users gave Kestra Medical Technologies an outperform vote while only 60.78% of users gave NeuroPace an outperform vote. CompanyUnderperformOutperformKestra Medical TechnologiesOutperform Votes571.43% Underperform Votes228.57% NeuroPaceOutperform Votes3160.78% Underperform Votes2039.22% SummaryKestra Medical Technologies beats NeuroPace on 8 of the 14 factors compared between the two stocks. Get NeuroPace News Delivered to You Automatically Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NPCE vs. The Competition Export to ExcelMetricNeuroPaceSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$392.38M$4.39B$5.57B$7.83BDividend YieldN/A39.98%5.11%4.22%P/E Ratio-11.6930.6722.4418.48Price / Sales4.7954.91394.09103.59Price / CashN/A51.0838.1834.62Price / Book14.806.116.774.25Net Income-$32.96M$68.15M$3.22B$248.23M7 Day Performance3.91%-0.12%1.49%0.89%1 Month Performance-10.83%-2.24%4.00%3.53%1 Year Performance-16.32%24.15%16.21%5.08% NeuroPace Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NPCENeuroPace3.8549 of 5 stars$11.69-2.4%$15.20+30.0%-10.0%$392.38M$79.91M-11.69170Upcoming EarningsShort Interest ↓Positive NewsKMTSKestra Medical TechnologiesN/A$25.12+3.6%$27.50+9.5%N/A$1.29B$52.64M0.00300PLSEPulse Biosciences1.161 of 5 stars$17.95+0.2%N/A+130.9%$1.21B$700,000.000.00140Upcoming EarningsPositive NewsCDRECadre3.7334 of 5 stars$29.42-3.4%$37.00+25.8%-12.6%$1.19B$567.56M35.452,240Upcoming EarningsPositive NewsTNDMTandem Diabetes Care4.6589 of 5 stars$17.47-3.3%$43.81+150.8%-54.1%$1.16B$940.20M-9.052,600News CoveragePositive NewsBLFSBioLife Solutions2.5591 of 5 stars$24.47-1.9%$31.17+27.4%+37.5%$1.16B$82.25M-23.08440Upcoming EarningsPositive NewsLQDALiquidia2.8422 of 5 stars$14.23+0.8%$26.63+87.1%+8.7%$1.10B$14.00M-8.7350FNAParagon 281.5234 of 5 stars$13.11+0.1%$14.20+8.4%+42.1%$1.10B$256.18M-17.71343,000High Trading VolumeAORTArtivion3.4992 of 5 stars$23.73-0.5%$31.40+32.3%+20.9%$1.01B$388.54M-1,186.501,300Upcoming EarningsNews CoverageMDXGMiMedx Group3.3954 of 5 stars$6.83-1.2%$12.00+75.7%+11.7%$1.01B$348.88M12.42870Earnings ReportNews CoveragePositive NewsINMDInMode3.4057 of 5 stars$14.26-12.1%$20.20+41.7%-18.0%$991.91M$394.82M6.07480Earnings ReportAnalyst ForecastOptions VolumeNews CoverageHigh Trading Volume Related Companies and Tools Related Companies Kestra Medical Technologies Alternatives Pulse Biosciences Alternatives Cadre Alternatives Tandem Diabetes Care Alternatives BioLife Solutions Alternatives Liquidia Alternatives Paragon 28 Alternatives Artivion Alternatives MiMedx Group Alternatives InMode Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NPCE) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroPace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NPCE Stock Free NPCE Stock Alerts